The sodium hyaluronic acid eye drops are mainly used for dry eye diseases and relieve dry eye symptoms; the main ingredient is sodium hyaluronic acid. Its chemical name: a mucopolysaccharide composed of disaccharide units composed of D-glucuronic acid and N-acetyl-D-glucosamine.

Founded in 1996, Shenzhen Ruilin is a professional sales company featuring general agent and academic promotion, with ophthalmology as its advantages, and focusing on the field of specialized medical care. Ruilin has successively joined forces with Japan HOYA, Germany Usfama Pharmaceuticals, South Korea LG, Switzerland AZDA, Japan Optoelectronics, Shantou Meiji Pharmaceuticals, Israeli Tiva, Hubei Keyi, Dandong Medical Chuang, Finland Icare, Germany Boehringer Ingelheim, and American Surgery Special equipment companies, American Anika and other companies have become partners. The current areas involved include ophthalmic drugs, consumables and devices, pain treatment, orthopedics, otolaryngology, liver disease, etc.

Currently, the company has more than 200 employees, 80% of them are in the marketing department. Shenzhen Ruilin has set up 34 liaison offices across the country and established a sales network covering the country. Ruilin sales are a marketing model that focuses on self-operation and supplements with investment. The marketing department is an important department of the company's marketing, responsible for product positioning, academic data production, training, marketing activity planning and implementation, sales target formulation, etc. Currently, there are nearly 20 people. The R&D & Registration Department is responsible for the research and development of company products and the registration of external cooperative varieties. Ruilin's business department is responsible for bidding, circulation, data collection, investment promotion and other work.

In recent years, Ruilin Pharmaceutical has begun to independently develop. Ruilin's early product, "Zuofu" (levofloxacin ear drops), obtained a new drug certificate and production approval document in 2009 and has been on the market for many years. Through international cooperation, one of the innovative drugs has global patents and is filed at the same time in China and the United States. It has completed the first phase of clinical practice in the United States and the second phase will begin in 2016. The project was also approved by the National 12th Five-Year Plan for Major New Drug Creation Project.

"Earning can change life, giving can create life." While Ruilin Medicine is constantly developing, it has not forgotten to give back to society. In 2011, Shenzhen Ruilin, in conjunction with Shenzhen Lions Club and the Ophthalmology Branch of the Chinese Medical Association, jointly established the "Ruilin Ophthalmology Clinical Rescue (Lions) Special Fund". Ruilin Pharmaceutical has promised to donate 1 million yuan every year for five consecutive years to help patients with eye diseases who cannot be effectively treated due to poverty receive timely treatment. The project has entered its second five-year rescue cycle. As of 2021, Ruilin Pharmaceutical has donated a total of 10 million yuan and jointly with 213 volunteer hospitals to rescue 3,300 patients. We believe: what we do, what they see.